Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).

Metenova is a leading innovator and manufacturer of magnetic mixers for pharmaceutical and biotechnology applications. The company is headquartered in Mölndal, Gothenburg.

The acquisition of Metenova strengthens Repligen's fluid management portfolio, with a product line that expands on the success of Repligen's systems and fluid management assemblies.

Vinge's team mainly consisted of Jonas Bergström, Johanna Wiberg, Viktor Lennartsson, Robin Sultani (M&A), Sam Seddigh, Hanna Marberg (employment), David Olander (competition), Mathilda Persson, Mika Jordan, Arthur Kinski, Mario Saad (commercial agreements), Christoffer Nordin (Life Science/Regulatory), Lisa Hörnqvist (IT and GDPR), Stojan Arnerstål, Axel Lennartsson, Johan Gavelin (IP), Kristoffer Larson (real property), Mia Falk (compliance), Anders Leissner (sanctions/export control) and Cecilia Loctander (project assistant).

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026

Vinge has advised United Lithium Corp. in connection with the acquisition of Swedish Minerals AB

United Lithium is an exploration & development company focused on the global demand for lithium, uranium and rare earth elements.
January 29, 2026